Press release article from our research archive:

Evalve's Percutaneous MitraClip(TM) Device Results in Significant Reverse Left Ventricular Remodeling.

Alternative to Major Open-Heart Surgery for Mitral Valve Repair Shows Ongoing Durability at Initial Three Year Follow-up More than 200 MitraClip Devices Implanted

MENLO PARK, Calif., March 26 /PRNewswire/ -- Evalve, Inc., a privately held medical device company, today announced data demonstrating that successful reduction of mitral regurgitation (MR) can be maintained for up to 36 months following treatment with the MitraClip device. The results at 12 months also show significant reverse left ventricular remodeling, indicating improved left ventricular function.

New EVEREST Registry data presented by Ted Feldman, M.D., director of the cardiac catheterization lab at ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!